Actively Recruiting
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Led by University Hospital, Bordeaux · Updated on 2026-01-15
30
Participants Needed
1
Research Sites
56 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Bordeaux
Lead Sponsor
B
Baxter Healthcare Corporation
Collaborating Sponsor
AI-Summary
What this Trial Is About
Sepsis remains a global scourge. Before the SARS-CoV-2 pandemic, the World Health Organization estimated approximately 49 million cases annually, resulting in 11 million deaths. Defined by dysregulated host response to infection, sepsis leads to vital organ failure. Renal dysfunction affects about half of ICU patients, necessitating extracorporeal renal replacement therapy in approximately 10% of cases, alongside coagulation system involvement typified by thrombocytopenia. Immunothrombotic phenomena are pivotal in sepsis pathophysiology, activating coagulation and disrupting immune responses. Microcirculatory impairment, mediated by neutrophils, monocytes, and platelets, worsens vital organ perfusion. Excessive production of Neutrophil Extracellular Traps (NETs) is implicated in microcirculatory compromise during sepsis.
CONDITIONS
Official Title
Immunothrombosis With Septic Shock Undergoing Renal Replacement Therapy With the OXIRIS Membrane
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and older
- Admitted to intensive care unit with septic shock defined by an increase in SOFA score of at least 2 points due to infection
- Requires vasopressor drugs to maintain mean arterial pressure 6 65 mmHg
- Has lactate level > 2 mmol/L despite adequate fluid resuscitation
- Requires renal replacement therapy according to consensus indications including KDIGO stage 3 acute kidney injury with oliguria or anuria for more than 72 hours, urea > 40 mmol/L, plasma potassium > 5.5 mmol/L despite treatment, pH < 7.15 with metabolic or mixed acidosis, or acute pulmonary edema with severe hypoxemia despite diuretic therapy
- Receiving continuous renal replacement therapy with either oXiris membrane or HF1400 membrane
You will not qualify if you...
- Known history of constitutional thrombopathy such as Bernard Soulier disease, Glanzmann thrombasthenia, Gray's syndrome, or dense granule disease
- Myelodysplastic or myeloproliferative syndrome
- Autoimmune thrombocytopenic purpura
- Acute leukemia
- Hemorrhagic shock
- Platelet transfusion within 7 days before inclusion
- Antiplatelet therapy with clopidogrel or ticagrelor within 5 days before inclusion, or prasugrel or dipyridamole within 7 days before inclusion
- Active HIV infection or hepatitis B or C
- Pregnant women
- Not affiliated with or benefiting from a social security system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Hopital Haut-Lévêque
Pessac, France, 33604
Actively Recruiting
Research Team
A
Antoine DEWITTE, Dr
CONTACT
S
Sarah CRONIER
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here